Compare Dishman Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs VENUS REMEDIES - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA VENUS REMEDIES DISHMAN PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 25.1 -1.0 - View Chart
P/BV x 3.3 0.1 4,706.4% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
VENUS REMEDIES
Mar-18
DISHMAN PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs374126 297.4%   
Low Rs12961 211.0%   
Sales per share (Unadj.) Rs197.8301.8 65.5%  
Earnings per share (Unadj.) Rs21.2-24.9 -85.3%  
Cash flow per share (Unadj.) Rs34.72.5 1,364.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9293.3 61.3%  
Shares outstanding (eoy) m80.6912.34 653.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 410.6%   
Avg P/E ratio x11.9-3.8 -315.7%  
P/CF ratio (eoy) x7.236.7 19.7%  
Price / Book Value ratio x1.40.3 438.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3061,154 1,759.9%   
No. of employees `0000.80.9 89.6%   
Total wages/salary Rs m5,355393 1,362.2%   
Avg. sales/employee Rs Th19,252.74,026.1 478.2%   
Avg. wages/employee Rs Th6,459.5425.0 1,520.0%   
Avg. net profit/employee Rs Th2,064.1-331.8 -622.1%   
INCOME DATA
Net Sales Rs m15,9613,724 428.6%  
Other income Rs m26523 1,179.6%   
Total revenues Rs m16,2263,747 433.1%   
Gross profit Rs m4,103395 1,039.3%  
Depreciation Rs m1,091338 322.4%   
Interest Rs m944354 266.6%   
Profit before tax Rs m2,334-275 -847.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62432 1,973.4%   
Profit after tax Rs m1,711-307 -557.5%  
Gross profit margin %25.710.6 242.5%  
Effective tax rate %26.7-11.5 -232.8%   
Net profit margin %10.7-8.2 -130.1%  
BALANCE SHEET DATA
Current assets Rs m11,0182,638 417.7%   
Current liabilities Rs m9,5172,305 412.9%   
Net working cap to sales %9.48.9 105.2%  
Current ratio x1.21.1 101.2%  
Inventory Days Days110135 81.6%  
Debtors Days Days3546 75.2%  
Net fixed assets Rs m16,3044,871 334.7%   
Share capital Rs m161123 130.8%   
"Free" reserves Rs m12,9073,496 369.2%   
Net worth Rs m14,5163,619 401.1%   
Long term debt Rs m4,1891,374 304.8%   
Total assets Rs m29,8057,509 397.0%  
Interest coverage x3.50.2 1,556.7%   
Debt to equity ratio x0.30.4 76.0%  
Sales to assets ratio x0.50.5 108.0%   
Return on assets %8.90.6 1,411.3%  
Return on equity %11.8-8.5 -139.0%  
Return on capital %17.51.6 1,108.1%  
Exports to sales %24.80-   
Imports to sales %3.713.9 26.9%   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596517 115.4%   
Fx inflow Rs m4,9520-   
Fx outflow Rs m697517 134.9%   
Net fx Rs m4,255-517 -823.8%   
CASH FLOW
From Operations Rs m2,786514 541.7%  
From Investments Rs m-1,529-123 1,242.0%  
From Financial Activity Rs m-941-387 243.1%  
Net Cashflow Rs m3164 7,533.3%  

Share Holding

Indian Promoters % 61.4 32.9 186.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.2 2,055.6%  
FIIs % 12.7 0.6 2,189.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 66.4 33.3%  
Shareholders   46,261 20,121 229.9%  
Pledged promoter(s) holding % 35.8 36.4 98.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS